SCHEDULE: Armistice Capital Discloses 7.76% Stake in Verastem

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 7,024,000 shares, representing 7.76% of Verastem, Inc.'s common stock, as of June 30, 2026.

Summary

• Armistice Capital, LLC, an investment manager, and its managing member Steven Boyd, have filed a Schedule 13G, indicating their beneficial ownership of 7,024,000 shares of Verastem, Inc. common stock.
• This holding represents 7.76% of the total class of securities.
• The filing is an amendment (Amendment No. 2) and the event date requiring the filing is June 30, 2026.
• Armistice Capital exercises voting and investment power over the securities held by its client, Armistice Capital Master Fund Ltd.
• Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own these securities.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting a significant but not overwhelming stake in Verastem, Inc. by Armistice Capital, LLC.

Positives

• Armistice Capital, LLC, a significant investment entity, has taken a notable stake in Verastem, Inc., signaling confidence or strategic interest.
• The reporting persons have shared voting and dispositive power over 7,024,000 shares, indicating active management of this investment.

Negatives

• The Master Fund, the direct holder of the shares, disclaims beneficial ownership due to the investment management agreement with Armistice Capital, which could imply a degree of separation in direct control.
• The filing does not provide specific reasons for the acquisition or increase in stake, leaving the strategic intent open to interpretation.

Risks

• Potential for increased market activity or volatility in Verastem, Inc. shares due to the significant stake held by an active investment manager.
• The investment strategy of Armistice Capital could lead to future changes in its holdings, impacting Verastem's stock price.

Future Outlook

This filing is primarily a disclosure of beneficial ownership and does not contain forward-looking statements or specific future guidance from Verastem, Inc. The future outlook for the investment depends on Armistice Capital's strategy and Verastem's business performance.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings often signal a shift in institutional ownership or a strategic interest from investment firms in the biotechnology or healthcare sector, where Verastem operates. This can precede further corporate actions or influence market perception.

Stakeholder Impact

• Shareholders: May see increased trading volume or price fluctuations due to the significant stake and active management by Armistice Capital.
• Management of Verastem, Inc.: May need to engage with Armistice Capital regarding their investment strategy and potential influence.

Next Steps

• Armistice Capital, LLC and Steven Boyd will continue to manage their beneficial ownership of Verastem, Inc. shares.
• Future amendments to this Schedule 13G will be filed if there are changes in beneficial ownership exceeding reporting thresholds.

Key Dates

Recommendation

The filing indicates a significant but not controlling stake by an investment manager. While it suggests institutional interest, it does not provide enough information about Verastem's performance or Armistice Capital's specific intentions to warrant a buy or sell recommendation. A 'hold' position allows for further observation of the company's strategic moves and the investor's actions.

Keywords

Verastem, Armistice Capital, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, Steven Boyd, Securities